Medical treatment of patients with atrial fibrillation aged over 80 years in daily clinical practice: Influence of age and CHADS2 score

Archives of Gerontology and Geriatrics

Volumn 50, Issue 1, 2010, Pages 36-41

  Lotze, Ulrich ^a,b   Liebetrau, Johannes ^b   Malsch, Ina ^b   Frühwirt, Benita ^b   Rothhagen, Brigitte ^b   Kharatyan, Natalya ^b   Neubauer, Katharina ^b  

^a Saale Unstrut Hospital Naumburg   (Germany)

^b Hospital Waltershausen Friedrichroda   (Germany)

Author keywords

Age and CHADS2 score; Atrial fibrillation; Medical treatment; Very elderly patients

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERTOPARIN; CLOPIDOGREL; DIGITALIS; DILTIAZEM; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; VERAPAMIL;

AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE HEART FAILURE, HYPERTENSION, AGE, DIABETES, PRIOR STROKE OR TRANSIENT ISCHEMIC ATTACK SCORE; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SYMPTOM; VERY ELDERLY;

AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; FRAIL ELDERLY; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70449722947     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2009.01.011     Document Type: Article

References (28)

1. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography. http://www.acc.org/qualityandscience/clinical/guidelines/echo/index.pdf.
2. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary. Eur. Heart J. 27, 1979-2030.
3. ®) in atrial fibrillation and TEE-guided cardioversion. Z. Kardiol. 92 (2003) 532-539
4. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silberschatz H., Kannel W.B., and Levy D. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 98 (1998) 946-952
5. Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavius, S., Yusuf, S., the ACTIVE Writing Group on behalf of the ACTIVE Investigators, 2006. Clopidogrel plus aspirin versus anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE-W): a randomised controlled trial. Lancet 367, 1903-1912.
6. Dharmarajan T.S., Varma S., Akkaladevi S., Lebelt A.S., and Norkus E.P. To anticoagulate or not to anticoagulate? A common dilemma for the provider: physicians' opinion poll based on a case study of an older long-term care facility resident with dementia and atrial fibrillation. J. Am. Med. Dir. Assoc. 7 (2006) 23-28
7. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclawiw M.A., and Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction: a retrospective analysis of the SOLVD trials. J. Am. Coll. Cardiol. 32 (1998) 695-703
8. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., and Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am. J. Cardiol. 74 (1994) 236-241
9. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., and Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J. Am. Med. Assoc. 285 (2001) 2864-2870
10. Gage B.F., van Walraven C., Pearce L., Hart R.G., Koudstaal P.J., Boode B.S., and Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110 (2004) 2287-2292
11. Glazer N.L., Dublin S., Smith N.L., French B., Jackson L.A., Hrachovec J.B., Siscovick D.S., Psaty B.M., and Heckbert S.R. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch. Intern. Med. 167 (2007) 246-252
12. Go A.S., Hylek E.M., Borowsky L.H., Philipps K.A., Selby J.V., and Singer D.E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (AT-RIA) study. Ann. Intern. 131 (1999) 927-934
13. Harenberg J., Weuster B., Pfitzer M., Dempfle C.E., Stehle G., Kübler W., and Schlierf G. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin. Thromb. Hemost. 19 Suppl. 1 (1993) 116-121
14. Kannel W.B., Wolf P.A., Benjamin E.J., and Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 82 (1998) 2N-9N
15. Latif A.K., Peng X., and Messinger-Rapport B.J. Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation. J. Am. Med. Dir. Assoc. 7 (2006) 334-335
16. Man-Song-Hing M., Nichol G., Lau A., and Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch. Intern. Med. 159 (1999) 677-685
17. Mant, J., Hobbs, F.D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G.Y., Murray, E., on behalf of the BAFTA investigators and Midland Research Practices Network (MidReC), 2007. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370, 493-503.
18. Nabauer, M., Gerth, A., Fetsch, T., Oeff, M., Ravens, U., Meinertz, T., Breithardt, G., Steinbeck, G., on behalf of The German Competence Network on Atrial Fibrillation, 2006. Use of antithrombotic treatment in daily medical practice in patients with atrial fibrillation: data from the central patient registry of the German Competence Network on Atrial Fibrillation. Eur. Heart J. 27(Abstract Suppl.), 38.
19. Nieuwlaat, R., Capucci, A., Camm, A.J., Olsson, S.B., Andresen, D., Davies, D.W., Cobbe, A., Breithardt, G., Le Heuzy, J.Y., Prins, M.H., Lévy, S., Crijns, H.J.G.M., on behalf of the Euro Heart Survey Investigators, 2005. Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euro Heart Survey on Atrial Fibrillation. Eur. Heart J. 26, 2422-2434.
20. Rash A., Downes T., Portner R., Yeo W.W., Morgan N., and Channer K.S. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 36 (2007) 151-156
21. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154 (1994) 1449-1457
22. Van Gelder I.C., Hagens V.A., Bosker H.A., Kingma J.H., Kamp O., Said S.A., Darmanata J.I., Timmermans A.J., Tijssen J.G., Crijns H.J., and for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347 (2002) 1834-1840
23. Van Walraven C., Hart R.G., Wells G.A., Petersen P., Koudstaal P.J., Gullov A.L., Hellemons B.S., Koefeld B.G., and Laupacis A. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch. Intern. Med. 163 (2003) 936-943
24. Vasishta S., Toor F., Johansen A., and Hasan M. Stroke prevention in atrial fibrillation: physicians' attitudes to anticoagulation in older people. Arch. Geront. Geriatr. 33 (2001) 219-226
25. White H.D., Gruber M., Feyzi J., Kaatz S., Tse H.F., Husted S., and Albers G.W. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med. 167 (2007) 239-245
26. Wolf P.A., Abbot R.D., and Kannel W.B. Atrial fibrillation: as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991) 983-988
27. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., Kellen J.C., Greene H.L., Mickel M.C., Dalquist J.E., Corley S.D., and the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347 (2002) 1825-1833
28. Yasaka M., and Ymaguchi T. Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation. C.N.S. Drugs 15 (2001) 623-631